Bufotalin
Based on 4 publication(s) in Google Scholar
Bufotalin is a steroid lactone isolated from Venenum Bufonis with potently antitumor activities. Bufotalin induces cancer cell apoptosis and also induces endoplasmic reticulum (ER) stress activation.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 471-95-4
- Formula: C26H36O6
- Molecular Weight:444.56
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Bufotalin
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
14 nM
Compound: 2a
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 23706005] |
| A549 | IC50 |
0.9 μM
Compound: 9
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 24050254] |
| A549 | IC50 |
4.21 μM
Compound: BT
|
Antitumor activity against human A549 cells xenografted in mouse assessed as tumor growth inhibition at 10 mg/ml,ip administrated for 21 days
Antitumor activity against human A549 cells xenografted in mouse assessed as tumor growth inhibition at 10 mg/ml,ip administrated for 21 days
|
[PMID: 38838547] |
| A549 | IC50 |
4.21 μM
Compound: BT
|
Antitumor activity against human A549 cells xenografted in mouse assessed as tumor growth inhibition at 5 mg/ml,ip administrated for 21 days
Antitumor activity against human A549 cells xenografted in mouse assessed as tumor growth inhibition at 5 mg/ml,ip administrated for 21 days
|
[PMID: 38838547] |
| B16-F10 | IC50 |
>10000 nM
Compound: 2a
|
Cytotoxicity against mouse B16F10 cells after 3 days by MTT assay
Cytotoxicity against mouse B16F10 cells after 3 days by MTT assay
|
[PMID: 23706005] |
| CT26.WT | IC50 |
>10000 nM
Compound: 2a
|
Cytotoxicity against mouse CT26.WT cells after 3 days by MTT assay
Cytotoxicity against mouse CT26.WT cells after 3 days by MTT assay
|
[PMID: 23706005] |
| HepG2 | IC50 |
0.5 μM
Compound: 9
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 24050254] |
| HL-60 | IC50 |
<0.01 μg/mL
Compound: 17
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 11575946] |
| Hs 683 | IC50 |
9 nM
Compound: 2a
|
Cytotoxicity against human Hs683 cells after 3 days by MTT assay
Cytotoxicity against human Hs683 cells after 3 days by MTT assay
|
[PMID: 23706005] |
| KB | IC50 |
0.19 μg/mL
Compound: 17
|
Cytotoxicity against human KB cells after 72 hrs by MTT assay
Cytotoxicity against human KB cells after 72 hrs by MTT assay
|
[PMID: 11575946] |
| MCF7 | IC50 |
37 nM
Compound: 2a
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 23706005] |
| MH60 | IC50 |
>25 μg/mL
Compound: 17
|
Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay
|
[PMID: 11575946] |
| MH60 | IC50 |
>56.2 μM
Compound: 7
|
Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
Growth inhibition of IL6-dependent mouse MH60 cells after 72 hrs by MTT assay in presence of human recombinant IL6
|
[PMID: 15620253] |
| MH60 | IC50 |
>56.2 μM
Compound: 7
|
Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
Growth inhibition of IL-6-independent mouse MH60 cells after 72 hrs by MTT assay
|
[PMID: 15620253] |
| PC-3 | IC50 |
34 nM
Compound: 2a
|
Cytotoxicity against human PC3 cells after 3 days by MTT assay
Cytotoxicity against human PC3 cells after 3 days by MTT assay
|
[PMID: 23706005] |
| SK-MEL-28 | IC50 |
65 nM
Compound: 2a
|
Cytotoxicity against human SK-MEL-28 cells after 3 days by MTT assay
Cytotoxicity against human SK-MEL-28 cells after 3 days by MTT assay
|
[PMID: 23706005] |
| U-373MG ATCC | IC50 |
74 nM
Compound: 2a
|
Cytotoxicity against human U373 cells after 3 days by MTT assay
Cytotoxicity against human U373 cells after 3 days by MTT assay
|
[PMID: 23706005] |
Bufotalin (0.1-2.5 μM; 12-96 hours) treatment dose- and time-dependently inhibits MG-63 osteoblastoma cell survival[1].
Bufotalin (0.5-2.5 μM; 48 hours) treatment dose-dependently increases the percentage of Annexin V positive cells (apoptotic cells) and caspase-12 activity in MG-63 cells. Bufotalin-induced osteoblastoma cell apoptosis is associated with caspase-12 activation[1].
Bufotalin (0.5-2.5 μM; 12 hours) treatment dose-dependently induces C/EBP homologous protein (CHOP) expression as well as PERK and IRE1 phosphorylation in MG-63 cells. Bufotalin induces endoplasmic reticulum (ER) stress activation in cells[1].
Bufotalin treatment induces cell cycle arrest at G2/M phase through down-regulation of Aurora A, CDC25, CDK1, cyclin A and cyclin B1, as well as up-regulation of p53 and p21 in HepG2 cells. Bufotalin treatment also induces apoptosis which was accompanied by decrease in mitochondrial membrane potential, increases in intracellular calcium level and reactive oxygen species production, activations of caspase-9 and -3, cleavage of poly ADP-ribose polymerase (PARP) as well as changes in the expressions of bcl-2 and bax[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MG-63 osteoblastoma cells
-
Concentration:0.1 μM, 0.5 μM, 1 μM, 2.5 μM
-
Incubation Time:12 hours, 24 hours, 48 hours, 72 hours, 96 hours
-
Result:Inhibited MG-63 osteoblastoma cell survival.
-
Cell Line:MG-63 cells
-
Concentration:0.5 μM, 1 μM, 2.5 μM
-
Incubation Time:48 hours
-
Result:Dose-dependently increased the percentage of Annexin V positive cells (apoptotic cells) and caspase-12 activity in MG-63 cells.
-
Cell Line:MG-63 cells
-
Concentration:0.5 μM, 1 μM, 2.5 μM
-
Incubation Time:12 hours
-
Result:Dose-dependently induced CHOP expression as well as PERK and IRE1 phosphorylation in MG-63 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID male mice (4-6 weeks old) injected with U2OS cells[1]
-
Dosage:0.5 mg/kg, 1 mg/kg
-
Administration:Intraperitoneal injection; twice daily; for 7 days
-
Result:Inhibited U2OS osteoblastoma cell growth in mice.
Chemical Information
-
CAS No. 471-95-4
-
Appearance Solid
-
Molecular Weight 444.56
-
Formula C26H36O6
-
Color White to off-white
-
SMILES
C[C@@]1(CC[C@@]2([H])[C@@]3([H])CC[C@@]4([H])[C@@]2(CC[C@H](O)C4)C)[C@@H](C(C=C5)=COC5=O)[C@@H](OC(C)=O)C[C@@]13O
-
Structure Classification
-
Initial Source
toad
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Pharmacol Res
2021 Dec:174:105927. PMID: 34740818 -
Phytomedicine
Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities. [Abstract]2024 Jan:123:155169. PMID: 37992493 -
Free Radic Biol Med
Bufotalin induces ferroptosis in non-small cell lung cancer cells by facilitating the ubiquitination and degradation of GPX4. [Abstract]2022 Feb 20:180:75-84. PMID: 35038550 -
Microb Pathog
2023 Jan:174:105918. PMID: 36455750
Solvent & Solubility
DMSO : 100 mg/mL (224.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhu YR, et al. Bufotalin-induced apoptosis in osteoblastoma cells is associated with endoplasmic reticulum stress activation. Biochem Biophys Res Commun. 2014 Aug 15;451(1):112-8. [Content Brief]
[2]. Zhang DM, et al. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Eur J Pharmacol. 2012 Oct 5;692(1-3):19-28. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2494 mL | 11.2471 mL | 22.4942 mL | 56.2354 mL |
| 5 mM | 0.4499 mL | 2.2494 mL | 4.4988 mL | 11.2471 mL | |
| 10 mM | 0.2249 mL | 1.1247 mL | 2.2494 mL | 5.6235 mL | |
| 15 mM | 0.1500 mL | 0.7498 mL | 1.4996 mL | 3.7490 mL | |
| 20 mM | 0.1125 mL | 0.5624 mL | 1.1247 mL | 2.8118 mL | |
| 25 mM | 0.0900 mL | 0.4499 mL | 0.8998 mL | 2.2494 mL | |
| 30 mM | 0.0750 mL | 0.3749 mL | 0.7498 mL | 1.8745 mL | |
| 40 mM | 0.0562 mL | 0.2812 mL | 0.5624 mL | 1.4059 mL | |
| 50 mM | 0.0450 mL | 0.2249 mL | 0.4499 mL | 1.1247 mL | |
| 60 mM | 0.0375 mL | 0.1875 mL | 0.3749 mL | 0.9373 mL | |
| 80 mM | 0.0281 mL | 0.1406 mL | 0.2812 mL | 0.7029 mL | |
| 100 mM | 0.0225 mL | 0.1125 mL | 0.2249 mL | 0.5624 mL |